Cargando…
CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers
BACKGROUND: The biological behaviors, clinical treatment, prognosis of non-muscle-invasive bladder cancers (NMIBCs) and muscle-invasive bladder cancers (MIBCs) are distinct. Accurate staging is pivotal in optimal therapy planning for bladder cancers (BCs). However, it is insufficient for urologists...
Autores principales: | Chen, Huang, Liu, Yu, Cao, Chuanzhen, Xi, Hao, Chen, Wenting, Zheng, Wei, Dong, Xin, Zheng, Shan, Li, Lin, Ma, Jianhui, Gao, Yanning, Shou, Jianzhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246191/ https://www.ncbi.nlm.nih.gov/pubmed/34268374 http://dx.doi.org/10.21037/atm-19-4511 |
Ejemplares similares
-
Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis
por: Fan, Yong, et al.
Publicado: (2019) -
CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma
por: Wei, Jing, et al.
Publicado: (2016) -
Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
por: Chu, Ling-Yu, et al.
Publicado: (2021) -
STROBE: The correlation of Cyr61, CTGF, and VEGF with polymyositis/dermatomyositis
por: Chai, Ke-Xia, et al.
Publicado: (2018) -
The Roles of CCN1/CYR61 in Pulmonary Diseases
por: Zhu, Yin, et al.
Publicado: (2020)